HFX iQ has already earned FDA approval in 2022, according to a news release. The spinal cord stimulator uses artificial intelligence combined with high-frequency therapy to help patients with chronic pain. It is indicated for back and leg pain, non-surgical refractory back pain, painful diabetic neuropathy, chronic upper limb and neck pain.
The company plans to launch the system in select European countries in early 2025.
